Added to YB: 2026-02-04
Pitch date: 2026-02-02
IDXG [bullish]
Interpace Biosciences, Inc.
-5.76%
current return
Author Info
The Micro-Capo is a blog where I share news and articles on companies I like or own. Sign up for the newsletter.
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
Market Cap
$55.4M
Pitch Price
$1.91
Price Target
4.50 (+150%)
Dividend
N/A
EV/EBITDA
10.32
P/E
2.30
EV/Sales
1.46
Sector
Health Care Providers and Services
Category
turnaround
The Micro-Capo | January 2026 - Interpace Biosciences, Inc.
IDXG (holding update): Thyroid diagnostics biz growing post-PancraGEN exit. Capital structure simplified - all preferred converted to common, debt eliminated. Sets stage for Nasdaq uplisting. $7-8M EBITDA by 2027 at 7-8x EV/EBITDA = $55-65M enterprise value, $3.50-$4.50/share target. Clean balance sheet, execution risk down.
Read full article (1 min)